Meeting
2022 ASCO Genitourinary Cancers Symposium
Overall survival (OS) after progression on first novel hormonal therapy (NHT) in patients (pts) with metastatic castration-sensitive versus castration-resistant prostate cancer (mCSPC versus mCRPC).
Authors
Nicolas Sayegh
Huntsman Cancer Institute-University of Utah Health Care, Salt Lake City, UT
Nicolas Sayegh , Nishita Tripathi , Taylor Ryan McFarland , Adam Kessel , Roberto Nussenzveig , Beverly Chigarira , Haoran Li , Clara Tandar , Divyam Goel , Blake Nordblad , Jackson Cheney , Kamal Kant Sahu , Benjamin L. Maughan , Umang Swami , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 121)
DOI
10.1200/JCO.2022.40.6_suppl.121
Abstract #
121
Poster Bd #
F10
Abstract Disclosures
Similar Posters
First Author: Elena Castro
Poster
2024 ASCO Genitourinary Cancers Symposium
Days spent with healthcare contact by patients with metastatic castrate-resistant prostate cancer in the last year of life.
First Author: Daniel Sentana Lledo
Poster
2023 ASCO Annual Meeting
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
First Author: Siyuan S Guo
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.
First Author: Elisabetta Malangone-Monaco